Drs Harrington and Gibson's annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights.
This podcast is intended for healthcare professionals only.
To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington
New ACS Guidelines
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
https://doi.org/10.1161/CIR.0000000000001309
ACS Guideline Chair and Vice-Chair Discussion
https://www.medscape.com/viewarticle/acs-guidelines-2025-key-points-chair-and-vice-chair-2025a100093l
Antiplatelet/Antithrombotic Strategies
Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI
https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET)
https://www.nejm.org/doi/full/10.1056/NEJMoa2507980
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC)
https://www.nejm.org/doi/full/10.1056/NEJMoa2507532
Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making : ENGAGE AF-TIMI 48 Trial Analysis
https://doi.org/10.1016/j.jacadv.2025.102504
Factor XI Inhibitors
Bristol Myers, J&J Stop Blood Clotting Drug Trial After Interim Review
https://www.medscape.com/s/viewarticle/bristol-myers-j-j-stop-blood-clotting-drug-trial-after-2025a1000vqu
Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention https://www.bayer.com/en/us/news-stories/oceanic-stroke
OAC-Naive Subgroup From OCEANIC-AF Published
https://www.medscape.com/viewarticle/novel-blood-thinner-shows-promise-atrial-fibrillation-2025a10008lz
GLP-1 and Myotrophic Drugs
Lilly's Next-gen Drug Shows Greater Weight Loss Than Zepbound in Late-stage Trial (TRIUMPH-4)
https://www.medscape.com/s/viewarticle/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-2025a1000ys1
Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial
https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf
CRISPR and Lipid Lowering
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa2504747
Gene Therapy Shows Lipid Improvement but Raises Flags
https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
https://www.nejm.org/doi/full/10.1056/NEJMoa2511778
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (VESALIUS-CV)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2514428
Prehospital GLP IIb/IIIa
Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268
You may also like:
Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology
https://www.medscape.com/twic
Questions or feedback, please contact [email protected]